Dermatology Times 2024 In Review: Hidradenitis Suppurativa
Phase 2a Study Demonstrates Dose-Dependent Tolerability of Oral Orismilast in Hidradenitis Suppurativa Results of this study may also be indicative of oral orismilast’s ability to contribute to meaningful clinical improvements, investigators noted. Lutikizumab Demonstrates Positive Results in Phase 2 Trial for Hidradenitis Suppurativa Higher response rates were observed in patients treated with lutikizumab and the … Read more